BVS logo

BIOVENTUS INC - A

BVSNASDAQ
πŸ† #2202 by market capEarnings Nov 3US Equity
$13.69β–Ό $0.16 (βˆ’1.16%)
Live
1hβ–² 1.4%
24hβ–Ό 1.2%
7dβ–Ό 10.3%
14dβ–² 4.5%
30dβ–² 13.5%
1yβ–² 87.1%
🏦Market Cap
$927M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+1.5%
Slowing
πŸ“ŠGross Margin
68.7%
High
πŸ’΅FCF Margin
17.5%
Healthy
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
62
Fair

Trading Snapshot

Day Range
$13.53 – $13.92
52-Week Range
$6.26 – $15.89
Volume
$2.81B
Avg Volume
$1.90B
Shares Outstanding
67.8M
Next Earnings
Sep 11, 2026

Fundamentals Snapshot

Annual Revenue
$568M
Last Q Revenue
$153M
P/E Ratio
41.2
P/S Ratio
2.0x
EPS (TTM)
$0.41
Dividend Yield
β€”

Why Investors Own BVS

  • βœ“High-growth profile β€” revenue up +17.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 51% gross margin and 26% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$568Mβ–² +12.5% YoY
Gross Margin (TTM)
51.1%β–² +3.4% YoY
Operating Income (TTM)
$214Mβ–² +12.5% YoY
Free Cash Flow (TTM)
$150Mβ–² +12.5% YoY

About BIOVENTUS INC - A

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
62/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

BenzingaΒ·5d ago

Deal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy

Major M&A deals include Visa buys BioCatch, Apollo Global nabs EasyJet, QVC emerges from Chapter 11 bankruptcy.

SeekingAlphaΒ·6d ago

Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation

2026-08-05. The following slide deck was published by Bioventus Inc.

SeekingAlphaΒ·7d ago

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Bioventus Inc. (BVS) Q2 2026 Earnings Call August 5, 2026 8:30 AM EDTCompany ParticipantsDavid Crawford - Vice President of Investor Relations &...

ChartMillΒ·7d ago

Bioventus (NASDAQ:BVS) Falls After Q2 Revenue Miss, Launches Strategic Review

Bioventus shares drop ~7% premarket on Q2 revenue miss, though EPS meets estimates; company launches strategic review.

πŸ›°οΈ
BenzingaΒ·7d ago

Bioventus Q2 Adj. EPS $0.22, Inline, Sales $153.208M Miss $155.640M Estimate

Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.22 per share which met the analyst consensus estimate. This is a 4.76 percent increase over earnings of $0.21 per share from the same period last year. The

🌌
BenzingaΒ·7d ago

Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est

Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000 million-$610.000 million